MediWoundMDWD
About: MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
Employees: 88
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
2.08% more ownership
Funds ownership: 39.01% [Q3] → 41.1% (+2.08%) [Q4]
2% more funds holding
Funds holding: 63 [Q3] → 64 (+1) [Q4]
4% more capital invested
Capital invested by funds: $76M [Q3] → $79M (+$2.95M) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
100% less call options, than puts
Call options by funds: $1K | Put options by funds: $480K
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Craig-Hallum Chase Knickerbocker 37% 1-year accuracy 10 / 27 met price target | 135%upside $39 | Buy Initiated | 28 Feb 2025 |
HC Wainwright & Co. Swayampakula Ramakanth 25% 1-year accuracy 49 / 198 met price target | 51%upside $25 | Buy Reiterated | 10 Jan 2025 |
Financial journalist opinion
Based on 5 articles about MDWD published over the past 30 days
